Loading
AB-3028 is an experimental autologous programmable circuit T cell therapy from Arsenal Biosciences, in phase 1 trials for metastatic castration-resistant prostate cancer.
AB-3028 is an autologous programmable circuit T cell therapy from Arsenal Biosciences. An autologous T cell therapy (the registry calls it a programmable circuit T cell therapy) for metastatic castration-resistant prostate cancer; patients must be PSMA-positive on PSMA PET, but no source reached states its targets. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07285694 active, not recruiting; started 9 January 2026. Whether it works in people has not been established unless a trial below reports it.
An autologous T cell therapy (the registry calls it a programmable circuit T cell therapy) for metastatic castration-resistant prostate cancer; patients must be PSMA-positive on PSMA PET, but no source reached states its targets.
1.AB-3028 slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AB-3028" OR ABSTRACT:"AB-3028") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AB-3028, not a curated reading list.
Shares Arsenal Biosciences and the tag pipeline.
Shares Arsenal Biosciences and the tag pipeline.
Shares Arsenal Biosciences and the tag pipeline.
Shares Arsenal Biosciences and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/